- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00889928
A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance (NOTES)
November 1, 2011 updated by: Ethicon Endo-Surgery
The study will document being able to successfully remove a subject's gallbladder through the vagina (laparoscopic visualization)using a small collection of study surgical tools.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University Feinberg School of Medicine - ATTN: Dr Hungness
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria
Women will be enrolled in this study who:
- Are willing to give consent and comply with evaluation and treatment schedule, able to understand and complete study questionnaires;
- At least 18 years of age;
- Have a clinical diagnosis of gallbladder disease indicated for cholecystectomy;
- ASA Classification I or II (Appendix II);
- Have a negative serum pregnancy test (for women of childbearing potential); and
- Absence, on visual inspection, of adhesions judged to be a potentially complicating factor in transvaginal access and operation.
Exclusion Criteria
Subjects will be excluded from the study for any of the following:
- BMI > 35;
- Use of immunosuppressive medications (within 6 months of surgery; single burst dosages and inhalable steroids are acceptable);
- Suspicion of gallbladder cancer, tumor, polyps, or mass;
- Acute cholecystitis or acute pancreatitis;
- Presence of common bile duct stones;
- History of cervical or vaginal cancer (or precancerous findings on most recent Pap Test);
- Pelvic Inflammatory Disease;
- Evidence of abdominal abscess or mass;
- Diffuse peritonitis;
- Use of anticoagulants or anti-platelet agents (use of daily cardio protective doses of aspirin, up to 81 mg/day, is acceptable and shall not constitute an exclusion criterion) or the presence of coagulopathy;
- Clinical diagnosis of sepsis;
- History of ectopic pregnancy, pelvic inflammatory disease, or severe endometriosis;
- History of peritoneal or vaginal trauma;
- Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or that could impact the scientific integrity of the trial;
- Planned concurrent surgical procedure;
- Prior or planned major surgical procedure within 30 days before or after study procedure;
- History of transvaginal surgery;
- History of (or symptomatic for) abdominal adhesions;
- Participation in any other investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints;
- Previously enrolled in the current series of 4 trials investigating the EES NOTES GEN1 Toolbox;
- Any contraindication listed in a study device Instructions for Use (IFU) document (if that device may be used in the study procedure); or
- Any condition which precludes compliance with the study (Investigator discretion).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: cholecystectomy
transvaginal cholecystectomy
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure Completion
Time Frame: Day of Surgery
|
Completion of procedure - transvaginal removal of the gallbladder
|
Day of Surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eric Hungness, MD, Northwestern University Feinberg School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (ACTUAL)
November 1, 2010
Study Completion (ACTUAL)
August 1, 2011
Study Registration Dates
First Submitted
April 28, 2009
First Submitted That Met QC Criteria
April 28, 2009
First Posted (ESTIMATE)
April 29, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
November 24, 2011
Last Update Submitted That Met QC Criteria
November 1, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CI-08-0004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gallbladder Disease
-
University of Medicine and Dentistry of New JerseyCompleted
-
Inje UniversityCompletedThe Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-InstrumentGallbladder DiseaseKorea, Republic of
-
Levita MagneticsCompleted
-
Merck Sharp & Dohme LLCCompleted
-
University Hospital, GenevaCompletedGallbladder DiseaseSwitzerland
-
Medtronic - MITGCompletedGallbladder DiseaseUnited States, Italy, United Kingdom
-
Kantonsspital Winterthur KSWUnknownBenign Gallbladder DiseaseSwitzerland
-
University of Alabama at BirminghamCompletedPancreatitis | Gallbladder DiseaseUnited States
-
Maltepe UniversityCompleted
-
University of PennsylvaniaLeonard Davis Institute of Health EconomicsRecruiting
Clinical Trials on NOTES GEN 1 Toolbox
-
Ethicon Endo-SurgeryCompleted
-
Ethicon Endo-SurgeryWithdrawnCholecystectomyUnited States
-
Seno Medical Instruments Inc.SuspendedBreast CancerUnited States
-
National Institutes of Health Clinical Center (CC)CompletedHIV Infection | Hepatitis CUnited States
-
ImunonCompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CancerUnited States
-
Portola PharmaceuticalsCompletedBleedingUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal CarcinomaUnited States
-
ASTORA Women's HealthCompletedPelvic Organ ProlapseUnited States, Belgium, France, Germany, Netherlands, Spain, United Kingdom
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated CarcinomaUnited States
-
Alexandria UniversityCompletedBacterial Keratitis | Fungal Keratitis | Mixed Bacterial and Fungal Keratitis | Microbial KeratitisEgypt